<SEC-DOCUMENT>0001157523-22-000518.txt : 20220502
<SEC-HEADER>0001157523-22-000518.hdr.sgml : 20220502
<ACCEPTANCE-DATETIME>20220502060151
ACCESSION NUMBER:		0001157523-22-000518
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		2
CONFORMED PERIOD OF REPORT:	20220502
FILED AS OF DATE:		20220502
DATE AS OF CHANGE:		20220502

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			FSD Pharma Inc.
		CENTRAL INDEX KEY:			0001771885
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			A6
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-39152
		FILM NUMBER:		22879192

	BUSINESS ADDRESS:	
		STREET 1:		FIRST CANADIAN PLACE
		STREET 2:		100 KING STREET WEST, SUITE 4000
		CITY:			TORONTO
		STATE:			A6
		ZIP:			M5X 1A4
		BUSINESS PHONE:		(416) 854-8884

	MAIL ADDRESS:	
		STREET 1:		FIRST CANADIAN PLACE
		STREET 2:		100 KING STREET WEST, SUITE 4000
		CITY:			TORONTO
		STATE:			A6
		ZIP:			M5X 1A4
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>a52703045.htm
<DESCRIPTION>FSD PHARMA INC. FORM 6-K
<TEXT>
<html>
  <head>
    <title></title>
    <!-- Licensed to: Business Wire
         Document created using EDGARfilings PROfile 8.1.0.0
         Copyright 1995 - 2022 Broadridge -->
  </head>
<body bgcolor="#ffffff" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000;">
  <div>
    <div><br>
    </div>
    <div><br>
    </div>
    <div>
      <div>
        <div style="text-align: center; color: rgb(35, 31, 32); font-weight: bold; font-size: 16pt;">UNITED STATES</div>
        <font style="font-size: 16pt;"> </font>
        <div style="text-align: center; color: rgb(35, 31, 32); font-weight: bold; font-size: 16pt;">SECURITIES AND EXCHANGE COMMISSION</div>
      </div>
      <div style="text-align: center; color: #231F20; font-weight: bold;">Washington, D.C. 20549</div>
      <div><br>
      </div>
      <div>
        <div style="text-align: center; color: rgb(35, 31, 32); font-weight: bold; font-size: 16pt;">Form 6-K</div>
      </div>
      <div><br>
      </div>
      <div style="text-align: center; color: #231F20; font-weight: bold;">REPORT OF FOREIGN PRIVATE ISSUER</div>
      <div style="text-align: center; color: #231F20; font-weight: bold;">PURSUANT TO RULE 13a-16 OR 15d-16</div>
      <div style="text-align: center; color: #231F20; font-weight: bold;">UNDER THE SECURITIES EXCHANGE ACT OF 1934</div>
      <div><br>
      </div>
      <div style="text-align: center; color: #231F20;">For the month of: <u><font style="font-weight: bold;">May 2022</font></u></div>
      <div><br>
      </div>
      <div style="text-align: center; color: #231F20;">Commission File Number: <font style="font-weight: bold;"><u>001-39152</u></font></div>
      <div><br>
      </div>
      <div>
        <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold; font-size: 16pt;">FSD PHARMA INC.</div>
        <div>
          <hr noshade="noshade" align="center" style="height: 2px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;"> </div>
      </div>
      <div style="text-align: center; color: #231F20;">(Translation of registrant&#8217;s name into English)</div>
      <div><br>
      </div>
      <div style="text-align: center;">199 Bay St., Suite 4000</div>
      <div style="text-align: center;">Toronto, Ontario M5L 1A9, Canada</div>
      <div>
        <hr noshade="noshade" align="center" style="height: 2px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;"> </div>
      <div style="text-align: center; color: #231F20;">(Address of principal executive office)</div>
      <div><br>
      </div>
      <div style="color: #231F20;">Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.</div>
      <div><br>
      </div>
      <div><font style="color: #231F20;">Form 20-F&#160;</font><font style="font-family: 'Segoe UI Symbol', sans-serif;">&#9744;</font><font style="text-indent: 0px; font-size: 5.14pt;" id="TRGRRTFtoHTMLTab">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="color: #231F20;">Form 40-F </font><font style="font-family: 'Segoe UI Symbol', sans-serif; color: #231F20;">&#9746;</font></div>
      <div><br>
      </div>
      <div style="color: #231F20;">Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ____</div>
      <div><br>
      </div>
      <div style="color: #231F20;">Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ____</div>
      <div><br>
      </div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
        <div style="page-break-after: always;" id="DSPFPageBreak">
          <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
      </div>
      <div><br>
      </div>
      <div style="text-align: center; color: #231F20; font-weight: bold;">SIGNATURES</div>
      <div>&#160;</div>
      <div>&#160;</div>
      <div style="text-indent: 36pt; color: #231F20;">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.</div>
      <div>&#160;</div>
      <div>&#160;</div>
      <div><br>
      </div>
      <div> <br>
      </div>
      <div>
        <table cellspacing="0" cellpadding="0" border="0" id="zab93401691be424a98fa232fdc0a64b1" style="width: 100%; border-collapse: separate; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">

            <tr>
              <td valign="top" style="width: 50%;">&#160;</td>
              <td valign="top" style="width: 38%;" colspan="2">FSD Pharma Inc.</td>
              <td valign="top" style="width: 12%;">&#160;</td>
            </tr>
            <tr>
              <td valign="top" style="width: 50%;" rowspan="1">&#160;</td>
              <td valign="top" style="width: 38%;" colspan="2" rowspan="1">(Registrant)</td>
              <td valign="top" style="width: 12%;" rowspan="1">&#160;</td>
            </tr>
            <tr>
              <td valign="top" style="width: 50%;" rowspan="1">&#160;</td>
              <td valign="top" style="width: 38%;" colspan="2" rowspan="1">&#160;</td>
              <td valign="top" style="width: 12%;" rowspan="1">&#160;</td>
            </tr>
            <tr>
              <td valign="top" style="width: 50%;">&#160;</td>
              <td valign="top" style="width: 3%;">&#160;</td>
              <td valign="top" style="width: 35%;">&#160;</td>
              <td valign="top" style="width: 12%;">&#160;</td>
            </tr>
            <tr>
              <td valign="top" align="left" style="width: 50%; padding-bottom: 2px;">
                <div align="left" style="margin-left: 0pt; text-indent: 0pt; margin-right: 0pt"><font style="color: #000000;">Date:&#160; </font>May 2, 2022</div>
              </td>
              <td valign="top" style="width: 3%; padding-bottom: 2px;">
                <div align="left" style="margin-left: 0pt; text-indent: 0pt; margin-right: 0pt">By: </div>
              </td>
              <td valign="top" nowrap="nowrap" align="left" style="width: 35%; border-bottom: #000000 2px solid">/s/&#160; <font style="color: #000000;">Nathan Coyle</font></td>
              <td valign="top" style="width: 12%; padding-bottom: 2px;">&#160;</td>
            </tr>
            <tr>
              <td valign="top" style="width: 50%;">&#160;</td>
              <td valign="top" style="width: 3%;">&#160;</td>
              <td valign="bottom" nowrap="nowrap" align="left" style="width: 35%;">Nathan Coyle, Chief Financial Officer</td>
              <td valign="top" style="width: 12%;">&#160;</td>
            </tr>

        </table>
        <div><br>
        </div>
      </div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
        <div style="page-break-after: always;" id="DSPFPageBreak">
          <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
      </div>
      <div> <br>
      </div>
      <div style="text-align: center; font-weight: bold;">EXHIBIT INDEX</div>
      <div>&#160;</div>
      <div>&#160;</div>
      <div>&#160;</div>
      <div>&#160;</div>
      <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;" id="ze0cee5880d9c4ef59628380e767ff9bc">

          <tr>
            <td style="width: 9%; vertical-align: middle;">
              <div style="color: #000000; font-weight: bold;"><u>Exhibit</u></div>
            </td>
            <td style="width: 91%; vertical-align: middle;">
              <div style="color: #000000; font-weight: bold;"><u>Description</u></div>
            </td>
          </tr>
          <tr>
            <td rowspan="1" style="width: 9%; vertical-align: top;">&#160;</td>
            <td rowspan="1" style="width: 91%; vertical-align: middle;">&#160;</td>
          </tr>
          <tr>
            <td style="width: 9%; vertical-align: top;"> <a href="a52703045ex99_1.htm">99.1</a><br>
            </td>
            <td style="width: 91%; vertical-align: middle; font-family: 'Times New Roman',Times,serif;">
              <div><a href="a52703045ex99_1.htm">Press Release &#8211; Dated May 2, 2021 FSD Pharma Announces Engagement with Tekkfund Capital and Share Issuance to Crystal
                  Research Associates</a></div>
            </td>
          </tr>

      </table>
      &#160; </div>
  </div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>a52703045ex99_1.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<html>
  <head>
    <title></title>
    <!-- Licensed to: Business Wire
         Document created using EDGARfilings PROfile 8.1.0.0
         Copyright 1995 - 2022 Broadridge -->
  </head>
<body bgcolor="#ffffff" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000;">
  <div>
    <table cellspacing="0" cellpadding="0" border="0" id="z1833ba28e8234d7aaab2df291b57b888" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; color: #000000; width: 100%;">

        <tr>
          <td style="width: 50.00%;">
            <div>&#160;</div>
          </td>
          <td style="width: 50.00%;">
            <div style="text-align: right;">&#160;<font style="font-weight: bold;">Exhibit 99.1</font></div>
          </td>
        </tr>

    </table>
    <div> <br>
    </div>
    <div> <br>
    </div>
    <div>
      <div class="bw-release">
        <h1 style="text-align: center; list-style-position: inside;FONT-SIZE: 14pt;"> <b>FSD Pharma Announces Engagement with Tekkfund Capital and Share Issuance to Crystal Research Associates</b> </h1>
        <div class="bw-release-body">
          <div class="bw-release-table-js bw-release-story">
            <p>TORONTO--(BUSINESS WIRE)--May 2, 2022--FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRE: 0K9A) (&#8220;<b>FSD Pharma</b>&#8221; or the &#8220;<b>Company</b>&#8221;), a life sciences holding company dedicated to building a portfolio of assets and biotech solutions,
              announced today that on April 15<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">th</sup>, 2022, the Company entered into a contract with Tekkfund Capital Corp (&#8220;<b>TCC</b>&#8221;) for services to structure and assist with certain business development strategies (the &#8220;<b>TCC Agreement</b>&#8221;),
              pursuant to which the Company will (i) pay TCC a monthly fee of C$12,500 plus HST; and (ii) issue, on a monthly basis, 7,000 Class B subordinate voting shares of the Company (&#8220;<b>TCC Consideration Shares</b>&#8221;) to TCC for the duration of the
              TCC Agreement, in accordance with the terms of the TCC Agreement. The TCC Agreement has an initial term of 24 months and may be extended by mutual consent of the parties. The TCC Consideration Shares will be subject to a four month hold
              period commencing on the date of distribution in accordance with Canadian Securities Exchange (&#8220;<b>CSE</b>&#8221;) requirements. </p>
            <p> In addition, on March 9<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">th</sup>, 2022, the Company issued 30,000 Class B subordinate voting shares (&#8220;<b>Crystal Consideration Shares</b>&#8221;) at the closing market price of the Company&#8217;s Class B subordinate voting shares on the CSE on the
              date of issuance to Crystal Research Associates, LLC (&#8220;<b>Crystal</b>&#8221;) in consideration for the preparation of the research report conducted by Crystal as previously disclosed in the Company&#8217;s press release dated March 15, 2022. The Crystal
              Consideration Shares are subject to a four month hold period commencing on the date of distribution in accordance with CSE requirements. </p>
            <p> <b>About FSD Pharma</b> </p>
            <p> FSD Pharma Inc., with only 38.4 million shares issued/outstanding, is a biotechnology company with three drug candidates in different stages of development. FSD BioSciences, Inc. (&#8220;<b>FSD BioSciences</b>&#8221;), a wholly owned subsidiary, is
              focused on pharmaceutical research and development of its lead compound, ultra-micronized palmitoyl ethylamine (&#8220;<b>PEA</b>&#8221;) or FSD-PEA (formerly called FSD-201). Lucid Psycheceuticals Inc. (&#8220;<b>Lucid</b>&#8221;), a wholly owned subsidiary, is
              focused on the research and development of its lead compounds, Lucid-PSYCH (formerly Lucid-201) and Lucid-MS (formerly Lucid-21-302). Lucid PSYCH is a molecular compound identified for the potential treatment of mental health disorders.
              Lucid-MS is a molecular compound identified for the potential treatment of neurodegenerative disorders. </p>
            <div> </div>
            <div style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt" id="DSPFPageBreakArea">
              <div style="PAGE-BREAK-AFTER: always" id="DSPFPageBreak">
                <hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000"> </div>
            </div>
            <p> <b>Forward Looking Information</b> </p>
            <p> Certain statements contained herein are &#8220;forward-looking statements.&#8221; Often, but not always, forward-looking statement can be identified by the use of words such as &#8220;plans&#8221;, &#8220;expects&#8221;, &#8220;expected&#8221;, &#8220;scheduled&#8221;, &#8220;estimates&#8221;, &#8220;intends&#8221;,
              &#8220;anticipates&#8221;, &#8220;hopes&#8221;, &#8220;planned&#8221; or &#8220;believes&#8221;, or variations of such words and phrases, or states that certain actions, events or results &#8220;may&#8221;, &#8220;could&#8221;, &#8220;would&#8221;, &#8220;might&#8221;, &#8220;potentially&#8221; or &#8220;will&#8221; be taken, occur or be achieved.
              Forward-looking statements contained in this press release include the comments made with respect to advancing the Company&#8217;s research into Lucid PSYCH, including the anticipated production and clinical development of Lucid-PSYCH and the
              advancement of Lucid PYSCH from research into clinical trials and any potential commercially viable therapeutic application, the efforts to advance ultramicronized Palmitoylethanolamide and develop of applications therefor evaluation of the
              commercial viability of its principal drug compound, and the statements made by Anthony Durkacz regarding the Company&#8217;s goal of rapidly moving Lucid-PSYCH from bench to clinic by obtaining IND approval and initiating a Phase 1 clinical study
              future development of Lucid PYSCH. FSD cannot give any assurance that such forward-looking statements will prove to have been correct. The reader is cautioned not to place undue reliance on these forward-looking statements, which speak only
              as of the date of this press release. </p>
            <p> Since forward-looking statements relate to future events and conditions, by their very nature they require making assumptions and involve inherent risks and uncertainties. The Company cautions that although it is believed that the
              assumptions are reasonable in the circumstances, these risks and uncertainties give rise to the possibility that actual results may differ materially from the expectations set out in the forward-looking statements. Factors that may cause such
              material differences include without limitation: the fact that the drug development efforts of both Lucid and FSD BioSciences are at a very early stage; the fact that preclinical drug development is uncertain, and the drug product candidates
              of Lucid and FSD BioSciences may never advance to clinical trials; the fact that results of preclinical studies and early-stage clinical trials may not be predictive of the results of later stage clinical trials; the uncertain outcome, cost,
              and timing of product development activities, preclinical studies and clinical trials of Lucid and FSD BioSciences; the uncertain clinical development process, including the risk that clinical trials may not have an effective design or
              generate positive results; the potential inability to obtain or maintain regulatory approval of the drug product candidates of Lucid and FSD BioSciences; the introduction of competing drugs that are safer, more effective or less expensive
              than, or otherwise superior to, the drug product candidates of Lucid and FSD BioSciences; the initiation, conduct, and completion of preclinical studies and clinical trials may be delayed, adversely affected, or impacted by COVID-19 related
              issues; the potential inability to obtain adequate financing; the potential inability to obtain or maintain intellectual property protection for the drug product candidates of Lucid and FSD BioSciences; and other risks. Further information
              regarding factors that may cause actual results to differ materially are included in the Company&#8217;s annual and other reports filed from time to time with the Canadian Securities Administrators on SEDAR (www.sedar.com) and with the U.S.
              Securities and Exchange Commission on EDGAR (www.sec.gov) under the heading &#8220;Risk Factors.&#8221; Any forward-looking statement contained in this release speaks only as of its date. The Company does not undertake to update any forward-looking
              statements, except to the extent required by applicable securities laws. </p>
          </div>
          <div class="bw-release-contact">
            <h2 style="FONT-SIZE: 14pt;">Contacts</h2>
            <p> Zeeshan Saeed, Founder, President and Executive Co-Chairman of the Board, FSD Pharma Inc. <br>
              Email: Zsaeed@fsdpharma.com<br>
              Telephone: (416) 854-8884 <br>
              <br>
              Investor Relations: <br>
              Email: ir@fsdpharma.com, info@fsdpharma.com<br>
              Website: www.fsdpharma.com </p>
          </div>
        </div>
      </div>
    </div>
  </div>
</body>
</html>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
